ArticleDiscover oncology2026
Development and validation of an interpretable prognostic model for bladder cancer based on lactylation associated genes using SHAP analysis.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe high recurrence rate and poor clinical outcomes of bladder cancer (BLCA) underscore the urgent need for novel biomarkers to guide precision medicine. Focusing on lactylation-a novel epigenetic modification-this study aimed to construct and validate a prognostic model for BLCA based on lactylation-related genes.
methodsTranscriptomic and clinical data were integrated from the Gene Expression Omnibus (GEO, GSE13507) and The Cancer Genome Atlas (TCGA-BLCA) cohorts. Core prognostic genes were identified, and a risk scoring model was constructed utilizing a stepwise framework comprising univariate Cox regression, Least Absolute Shrinkage and Selection Operator (LASSO) regression, and multivariate Cox regression. The SHapley Additive exPlanations (SHAP) algorithm was employed for personalized, interpretable survival predictions. Subsequently, the associations between the risk model and the tumor immune microenvironment (TIME), tumor mutational burden (TMB), and drug sensitivity were comprehensively evaluated.
resultsA 4-gene risk model comprising ATAD3A, MKI67, VWF, and CCL2 was ultimately established. The model demonstrated robust predictive efficacy in both the training cohort (1-, 3-, and 5-year AUCs of 0.802, 0.818, and 0.856, respectively) and the validation cohort (AUCs of 0.636, 0.601, and 0.627, respectively). Multivariate analysis confirmed that the risk score served as an independent prognostic factor. The SHAP analysis facilitated precise interpretability, bridging global feature importance with individual mortality risk. Immune infiltration profiling revealed a significant enrichment of M2 macrophages coupled with high CCL2 expression in the high-risk group. Furthermore, combined survival analysis indicated that patients with a "low TMB and high-risk" profile exhibited the poorest clinical outcomes.
conclusionTo our knowledge, this study is the first to establish a 4-gene lactylation-related prognostic model for BLCA integrating a LASSO-SHAP framework. This model not only provides precise, visualizable predictions for individualized survival risk but also elucidates the lactylation-driven immunosuppressive microenvironment in BLCA, offering crucial data support for the development of personalized immunotherapeutic and targeted strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.